Understanding Your Diagnosis: PLAID and APLAID

Receiving a diagnosis of a PLCG2-associated disease often marks the end of a long and exhausting “diagnostic odyssey.” Because these conditions are ultra-rare—with only a small number of families reported in the medical literature—many families spend years visiting different specialists before finding an answer ^[1][2].

These conditions are caused by changes (variants) in the PLCG2 gene. This gene provides instructions for making an enzyme called PLCγ2, which acts as a critical signal transmitter for your immune system ^[3]. When this mechanism is altered, it can cause the immune system to either overreact without infection (autoinflammation) or underperform (immune deficiency), and sometimes both at once ^[4].

The Role of the PLCγ2 Enzyme

The PLCγ2 enzyme is primarily found in immune cells, including B cells (which make antibodies) and Natural Killer (NK) cells (which fight viruses and tumors) ^[3][5].

In a healthy immune system, when a cell detects a threat, it activates PLCγ2. The enzyme then creates messenger molecules (IP3 and DAG) that tell the cell to release calcium and start an immune response ^[3][6].

• In B cells: This process helps the body create protective antibodies ^[5].
• In Myeloid cells: It helps white blood cells clear debris and respond to infection ^[7].
• In NK cells: It allows the cells to destroy infected or abnormal cells ^[8].

In patients with these conditions, the PLCγ2 enzyme is either too active (gain-of-function) or not active enough (loss-of-function), leading to a wide variety of symptoms ^[4].

Two Main Spectrums: PLAID and APLAID

Doctors generally divide these diseases into two typical patterns based on the patient’s symptoms and how the enzyme behaves, though modern research shows these categories can often overlap ^[9].

PLAID (PLCG2-associated Antibody Deficiency and Immune Dysregulation)

The hallmark of PLAID is cold urticaria—hives or skin swelling triggered by exposure to cold air, cold water, or even the cooling effect of evaporating sweat ^[10][11].

• The Cause: In typical PLAID, a gain-of-function variant makes the enzyme relatively “quiet” at normal body temperature but hyperactive the moment the temperature drops even slightly ^[12].
• Other Features: While cold hives are the most prominent sign, patients often also develop antibody deficiency (low levels of protective proteins in the blood), an increased risk of autoimmune diseases, or granulomas (small clumps of inflammatory cells in the skin) ^[10][13].

APLAID (Autoinflammation and PLAID)

APLAID is typically more severe and starts earlier in life, often with skin blistering or pustules in the first weeks of infancy ^[1][14].

• The Cause: Unlike PLAID, the enzyme in APLAID is usually continuously active even at normal body temperature ^[15].
• Other Features: Patients may experience widespread autoinflammation, which is inappropriate immune activation. This can affect the eyes (redness and pain), the lungs, the gastrointestinal tract, and the joints ^[1][16]. Like PLAID, patients often have low antibody levels and a risk of recurrent infections ^[17].

Understanding Genetic Variants

Not all PLCG2 diseases are the same because different types of genetic changes cause the enzyme to behave differently.

1. Gain-of-Function (GOF): Most cases of classic PLAID and APLAID are caused by GOF variants. The enzyme triggers too easily. In APLAID, it stays active at 37°C (body temperature), while in PLAID, it typically activates when cooled ^[15][12].
2. Loss-of-Function (LOF): A distinct and heterogeneous phenotype occurs when LOF variants are present. The enzyme is weak or inactive. These patients might not have cold hives or autoinflammation, but can have severe immune deficiency, such as a high susceptibility to herpesviruses (like the virus that causes cold sores or chickenpox) because their NK cells cannot function properly, depending on the specific variant and functional results ^[8][4].

How Rare Are These Conditions?

These are considered “ultra-rare” diseases. Because they were only recently discovered (the first major reports were in 2012), the exact number of people affected is unknown. Current medical literature mostly consists of small case studies ^[1][14]. Because it is so rare, your care will likely require a team of specialists—including immunologists and geneticists—who may collaborate with national research institutions to stay updated on the latest findings.